YSYanhong Sun

Yanhong Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanhong Sun has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Bihui Zhong

    Department of Gastroenterology The First Affiliated Hospital, Sun Yat‐sen University Guangzhou China

    3 shared publications
  • Junzhao Ye

    Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    2 shared publications
  • Ling Luo

    Department of Infectious Diseases The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong China

    2 shared publications
  • Wei Wang

    Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China

    2 shared publications
  • Congxiang Shao

    Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    1 shared publication
  • Jiaming Lai

    Department of Gastroenterology The First Affiliated Hospital Sun Yat-sen University No. 58 Zhongshan II Road Yuexiu District Guangzhou China

    1 shared publication

Latest Publications

  • Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis

    by Junzhao Ye, Jiaming Lai, Ling Luo, Ting Zhou, Yanhong Sun, Bihui Zhong


  • Open Access

    Comparisons of Post-Load Glucose at Different Time Points for Identifying High Risks of MASLD Progression

    by Long Teng, Ling Luo, Yanhong Sun, Wei Wang, Zhi Dong, Xiaopei Cao, Junzhao Ye, Bihui Zhong

    Background: The 1-h post-load plasma glucose was proposed to replace the current OGTT criteria for diagnosing prediabetes/diabetes. However, it remains unclear whether it is superior in identifying progressive metabolic dysfunction-associated steatotic liver disease (MASLD), and thus we aimed to clarify this issue. Methods: Consecutive Asian participants (non-MASLD, n = 1049; MASLD, n = 1165) were retrospectively enrolled between June 2012 and June 2024. CT was used to quantify liver steatosis, while the serum liver fibrotic marker was used to evaluate liver fibrosis. Results: Compared with those with normal levels of both 1-h post-glucose (1hPG) and 2-h post-glucose (2hPG), patients with MASLD showed a significant positive association between elevated 1hPG levels and moderate to severe liver steatosis (odds ratio [OR] = 2.19, 95% confidence interval [CI]: 1.13–4.25, p = 0.02]. Elevated levels of both 1hPG and 2hPG were associated with an increased risk of liver injury (OR = 2.03, 95% CI: 1.44–2.86, p < 0.001). Elevated 2hPG levels with or without elevated 1hPG levels were associated with liver fibrosis (OR = 1.99, 95% CI: 1.15–3.45, p < 0.001; OR = 2.72, 95% CI: 1.79–4.11, p < 0.001, respectively). Additionally, either 1hPG or 2hPG levels were associated with atherosclerosis, revealing significant dose-dependent associations between glucose status and atherosclerosis risk (OR = 2.77, 95% CI: 1.55–4.96, p < 0.001 for elevated 1hPG; OR = 2.98, 95% CI = 1.54–5.78, p = 0.001 for elevated 2hPG; OR = 2.41, 95% CI = 1.38–4.21, p = 0.001 for elevated levels of both 1hPG and 2hPG). The areas under the ROC for predicting steatosis, liver injury, liver fibrosis, and atherosclerosis were 0.64, 0.58, 0.58, and 0.64 for elevated 1hPG (all p < 0.05) and 0.50, 0.60, 0.56, and 0.62 for elevated 2hPG (all p < 0.05), respectively. Conclusions: These findings underscore the necessity for clinicians to acknowledge that the screening and management of MALSD requires the monitoring of 1hPG levels.


  • Open Access

    Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection

    by Ling Luo, Junzhao Ye, Congxiang Shao, Yansong Lin, Yanhong Sun, Shiting Feng, Wei Wang, Bihui Zhong

    Whether the associations between serum vitamin D (VitD) and metabolic-associated fatty liver disease (MAFLD) vary with chronic hepatitis B (CHB) infection has not been well established. This study aims to investigate the relationships between serum VitD and metabolism, liver fat content (LFC) and fibrosis among MAFLD patients with and without CHB. Consecutive subjects (healthy controls: 360, CHB: 684, MAFLD: 521, CHB with MAFLD: 206) were prospectively enrolled between January 2015 and December 2021. Anthropometric, laboratory, imaging, and histological evaluations were conducted, with LFC measured via magnetic resonance imaging-based proton density fat fraction (MRI-PDFF). Serum VitD levels were lower in MAFLD patients than in healthy controls and patients with CHB alone or overlapping with MAFLD (24.4 ± 8.1 vs. 29.0 ± 9.5 vs. 27.4 ± 9.6 vs. 26.8 ± 8.4 ng/mL respectively; p < 0.001 in one-way ANOVA test). After adjusting for confounding factors, including season, hypersensitive C-reactive protein, insulin resistance, liver stiffness measurements, sun exposure, exercise and dietary intake, multivariate linear regression analysis revealed that VitD remained significantly negatively correlated with LFC in MAFLD patients (β = −0.38, p < 0.001), but not in CHB with MAFLD patients. Moreover, quantile regression models also demonstrated that lower VitD tertiles were inversely associated with the risk of insulin resistance and moderate–severe steatosis in the MAFLD group (p for trend <0.05) but not in the MAFLD with CHB group. VitD deficiency was associated with the severity of metabolic abnormalities and steatosis independent of lifestyle factors in MAFLD-alone subjects but not in MAFLD with CHB subjects.